The clinical application of monoclonal antibody therapies in renal transplantation

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.9.1.23PMID 15155134
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients

  2012cited by this paper
• Pillars Article: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256 (5517): 495–497.

  2005cited by this paper
• The natural history of chronic allograft nephropathy.

  2005cited by this paper
• Homeostatic proliferation is a barrier to transplantation tolerance

  2004cited by this paper
• Bone disease after kidney transplantation.

  2004cited by this paper
• Functional Antibodies to Leukocyte Adhesion Molecules in Antithymocyte Globulins.

  2003cited by this paper
• Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

  2003cited by this paper
• Lipid Profile Before and After Renal Transplantation—A Longitudinal Study

  2003cited by this paper
• Treatment of acute kidney allograft rejection with a non‐mitogenic CD3 antibody

  2003cited by this paper
• The natural history of chronic allograft nephropathy.

  2003cited by this paper
• Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

  2003cited by this paper
• Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

  2003cited by this paper
• Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

  2003cited by this paper
• Campath‐1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study

  2003cited by this paper
• Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1

  2003cited by this paper
• Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins1

  2003cited by this paper
• Humanized anti‐CD20 monoclonal antibody (Rituximab) treatment for post‐transplant lymphoproliferative disorder *

  2003cited by this paper
• RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52‐SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH‐1H)

  2003cited by this paper
• Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

  2002cited by this paper
• Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy

  2002cited by this paper
• Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

  2002cited by this paper
• Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.

  2002cited by this paper
• Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates.

  2002cited by this paper
• INDUCTION THERAPY WITH MONOCLONAL ANTIBODIES SPECIFIC FOR CD80 AND CD86 DELAYS THE ONSET OF ACUTE RENAL ALLOGRAFT REJECTION IN NON-HUMAN PRIMATES1

  2001influential reference
• Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of 
anti‐αGal antibody

  2001cited by this paper
• The role of CD154 in organ transplant rejection and acceptance.

  2001influential reference
• A randomized prospective trial of OKT3 induction in the current immunosuppression era

  2001cited by this paper
• Hypertension after renal transplantation

  2001cited by this paper
• ECONOMIC ANALYSIS OF BASILIXIMAB IN RENAL TRANSPLANTATION1

  2001cited by this paper
• Economic analysis of basiliximab in renal transplantation.

  2001cited by this paper
• MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION

  2001cited by this paper
• Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.

  2000cited by this paper
• A Model System for Activation-Induced Alternative Splicing of CD45 Pre-mRNA in T Cells Implicates Protein Kinase C and Ras

  2000cited by this paper
• An Essential Contribution by IFN-γ to CD8+ T Cell-Mediated Rejection of Pancreatic Islet Allografts1

  2000cited by this paper
• Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.

  2000cited by this paper
• The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.

  2000cited by this paper
• Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

  2000cited by this paper
• Cancers in renal transplant recipients.

  2000cited by this paper
• Graft tolerance: A duel of two signals

  1999cited by this paper
• A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.

  1999cited by this paper
• Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.

  1999cited by this paper
• Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates

  1999cited by this paper
• A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group.

  1999cited by this paper
• Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

  1999cited by this paper
• CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

  1999cited by this paper
• Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

  1998cited by this paper
• Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction

  1998cited by this paper
• CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

  1998influential reference
• Cell adhesion molecules in clinical renal transplantation.

  1998cited by this paper
• Two low‐dose OKT3 induction regimens following renal transplantation – clinical experience at a single center

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• Inhaled nitric oxide and heparin for infantile primary pulmonary hypertension.

  1998cited by this paper
• Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.

  1998cited by this paper
• Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

  1997cited by this paper
• Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions.

  1997cited by this paper
• Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group.

  1997cited by this paper
• Analysis of CD40‐CD40 Ligand Interactions in the Regulation of Human B Cell Function a

  1997cited by this paper
• Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study.

  1997cited by this paper
• Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts.

  1997cited by this paper
• CD28 co-receptor signal transduction in T-cell activation.

  1997influential reference
• Prevention of rejection with BTI-322 after renal transplantation (results at 9 months).

  1997cited by this paper
• FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts.

  1997cited by this paper
• CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

  1997cited by this paper
• Muromonab CD3

  1996cited by this paper
• A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.

  1996cited by this paper
• Anti-CD4 MoAb therapy in kidney transplantation--a pilot study in early prophylaxis of rejection.

  1996cited by this paper
• CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2

  1995cited by this paper
• T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction.

  1995cited by this paper
• Mechanisms of Action and Overview of OKT3

  1995cited by this paper
• The CD28 and CTLA-4 Receptor Family (Part 1 of 2)

  1994cited by this paper
• CAMPATH-1 Monoclonal Antibodies in Bone Marrow Transplantation

  1994cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2

  1994cited by this paper
• The CD28 and CTLA-4 receptor family.

  1994influential reference
• A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.

  1994cited by this paper
• The B7 and CD28 receptor families.

  1994influential reference
• A NON‐ACTIVATING “HUMANIZED” ANTI‐CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO

  1994cited by this paper
• In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

  1994cited by this paper
• Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction.

  1993cited by this paper
• A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients.

  1993cited by this paper
• The IL-2/IL-2 receptor system: a current overview.

  1993cited by this paper
• Fine needle aspiration biopsy in renal transplant patients on prophylactic OKT3 treatment.

  1992cited by this paper
• INDUCTION OF TRANSPLANTATION TOLERANCE IN ADULTS USING DONOR ANTIGEN AND ANTI‐CD4 MONOCLONAL ANTIBODY

  1992cited by this paper
• Reversal of allograft rejection using the monoclonal antibody, Campath-1G.

  1991cited by this paper
• IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS

  1990cited by this paper
• Role of lymphokine in islet allograft rejection.

  1990cited by this paper
• The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging.

  1990cited by this paper
• Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody.

  1990cited by this paper
• In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts.

  1990cited by this paper
• Activation of tyrosine phosphorylation in human T cells via the CD2 pathway. Regulation by the CD45 tyrosine phosphatase.

  1990cited by this paper
• Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes.

  1989influential reference
• RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS

  1989cited by this paper
• CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

  1989influential reference
• The leukocyte common antigen family.

  1989cited by this paper
• Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.

  1989cited by this paper
• Two leukocyte receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands.

  1989cited by this paper
• Bivalent binding of an anti-CD3 antibody to Jurkat cells induces association of the T cell receptor complex with the cytoskeleton.

  1989cited by this paper
• T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1

  1989cited by this paper

• Efficient detection of eukaryotic calcium-sensing receptor (CaSR) by polyclonal antibody against prokaryotic expressed truncated CaSR

  2020cites this paper
• Blockade of KATP Channels Reduces Endothelial Hyperpolarization and Leukocyte Recruitment upon Reperfusion After Hypoxia

  2009cites this paper
• The use of biologics in transplantation: a new era

  2006cites this paper